1
/
of
1
Elabscience
SKU:E-EL-H0983
Human SNCα(Synuclein Alpha) ELISA Kit
Human SNCα(Synuclein Alpha) ELISA Kit
Regular price
$609.00 USD
Regular price
Sale price
$609.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the HUMAN SNCΑ (SYNUCLEIN ALPHA) ELISA KIT, a cutting-edge solution designed to facilitate accurate and efficient detection of Synuclein Alpha in human samples. This advanced kit is meticulously crafted to meet the highest standards of quality and reliability, ensuring precise and reproducible results.
The HUMAN SNCΑ ELISA KIT employs a highly sensitive enzyme-linked immunosorbent assay (ELISA) technique, enabling the quantification of Synuclein Alpha with exceptional sensitivity and specificity. By utilizing state-of-the-art antibodies and reagents, this kit guarantees optimal performance and robustness in detecting even the lowest concentrations of Synuclein Alpha.
With its user-friendly design, the HUMAN SNCΑ ELISA KIT offers a streamlined workflow, allowing for seamless integration into laboratory protocols. The comprehensive kit includes all necessary components, including pre-coated microplates, standards, controls, and detection reagents, ensuring convenience and efficiency in experimental procedures.
Furthermore, the HUMAN SNCΑ ELISA KIT provides a wide dynamic range, enabling accurate quantification of Synuclein Alpha across a broad spectrum of concentrations. This versatility makes it an invaluable tool for various research applications, such as biomarker discovery, disease progression monitoring, and therapeutic efficacy assessment.
Rest assured, the HUMAN SNCΑ ELISA KIT adheres to stringent quality control measures, guaranteeing the utmost accuracy and reproducibility of results. Each batch undergoes rigorous testing to ensure consistent performance, providing researchers with reliable data for their scientific investigations.
In summary, the HUMAN SNCΑ (SYNUCLEIN ALPHA) ELISA KIT is a state-of-the-art solution that empowers researchers with the ability to accurately and efficiently detect Synuclein Alpha in human samples. With its exceptional sensitivity, user-friendly design, and reliable performance, this kit is an indispensable asset for advancing scientific understanding and driving breakthrough discoveries in the field of neurodegenerative diseases.
The HUMAN SNCΑ ELISA KIT employs a highly sensitive enzyme-linked immunosorbent assay (ELISA) technique, enabling the quantification of Synuclein Alpha with exceptional sensitivity and specificity. By utilizing state-of-the-art antibodies and reagents, this kit guarantees optimal performance and robustness in detecting even the lowest concentrations of Synuclein Alpha.
With its user-friendly design, the HUMAN SNCΑ ELISA KIT offers a streamlined workflow, allowing for seamless integration into laboratory protocols. The comprehensive kit includes all necessary components, including pre-coated microplates, standards, controls, and detection reagents, ensuring convenience and efficiency in experimental procedures.
Furthermore, the HUMAN SNCΑ ELISA KIT provides a wide dynamic range, enabling accurate quantification of Synuclein Alpha across a broad spectrum of concentrations. This versatility makes it an invaluable tool for various research applications, such as biomarker discovery, disease progression monitoring, and therapeutic efficacy assessment.
Rest assured, the HUMAN SNCΑ ELISA KIT adheres to stringent quality control measures, guaranteeing the utmost accuracy and reproducibility of results. Each batch undergoes rigorous testing to ensure consistent performance, providing researchers with reliable data for their scientific investigations.
In summary, the HUMAN SNCΑ (SYNUCLEIN ALPHA) ELISA KIT is a state-of-the-art solution that empowers researchers with the ability to accurately and efficiently detect Synuclein Alpha in human samples. With its exceptional sensitivity, user-friendly design, and reliable performance, this kit is an indispensable asset for advancing scientific understanding and driving breakthrough discoveries in the field of neurodegenerative diseases.
Share
